Cancer, Lung Cancer Metastatic, MET Gene Mutation
Conditions
Brief summary
This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.
Interventions
DRUGCapmatinib
Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
Sponsors
Asan Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with histologically or cytologically confirmed, unresectable stage IIIB/IV NSCLC that carries MET exon 14 skipping alteration by molecular testing, as per NGS and RT PCR. * ECOG performance status of 0 to 2 * Male or female; ≥ 18 * Subjects with measurable lesion (using RECIST 1.1 criteria) * Subjects must have archival tissue sample available, collected either at the time of diagnosis of NSCLC or any time since * Patients who have progressed during or after 1st line or 2nd line therapy prior to the first dose of capmatinib. For patient who have received prior platinum containing adjuvant, neoadjuvant, or definitive chemoradiation for locally advanced disease, those treatments are regarded as 1st line if the progression has occurred \< 12 months from last therapy.
Exclusion criteria
* Any major operation or irradiation within 4 weeks of baseline disease assessment * Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug * Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms * Patients who have received more than 2 lines of prior systemic therapy, which include chemo, immune and targeted therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months] | ORR is a proportion of patients with a best overall response defined as complete response or partial response by RECIST1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of response | At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months | DOR is calculated as the time from the date of the first document of complete remission (CR) or partial remission (PR) to the first documented preogressive disease (PD) or death due to any cause for patients with PR or CR. |
| Progression-free survival | At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months | PFS is defined as time from the first dose of investigational products (IPs) to progression or death due to any cause. OS is defined as time from the first dose of IPs to death due to any cause. |
| Overall survival | At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months | — |
Countries
South Korea
Outcome results
None listed